Humana (HUM) risk factors, FY2024 10-K

Humana's FY2024 10-K, filed Feb 20, 2025, lists 22 risk factors. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Risk factors listed
221 groups
Section length
11k wordsItem 1A

Humana's biggest risks in the FY2024 10-K

  • Heavy reliance on government health care programs, accounting for approximately 94% of total premiums and services revenue.

The risks most specific to Humana

  • Risks Relating to Our Business

    on our ability to appropriately manage health care costs through, among other things, the application of medical management programs such as our chronic care management program

    Medical management programs, such as chronic care management, may fail to appropriately control health care costs.

  • Risks Relating to Our Business

    primary care, and home solutions businesses, and the successful implementation of our integrated care delivery model

    Substantial reliance and revenue concentration in Medicare products increase our strategic and financial exposure.

  • Risks Relating to Our Business

    As a government contractor, we are exposed to risks that may materially adversely affect our business or our willingness or ability to participate in government health care programs

    Government health care programs, including Medicare, Medicaid, and military services, accounted for approximately 94% of our total revenues in 2024.

  • Risks Relating to Our Business

    conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model

    CMS and HHS-OIG audits, known as RADV audits, target our risk adjustment diagnosis data submissions and compliance efforts.

  • Risks Relating to Our Business

    Corporate Practice of Medicine and Other Laws

    State corporate practice of medicine laws restrict our ability as a corporate entity to control physicians' medical decisions.

  • Risks Relating to Our Business

    Our in-house dispensing pharmacy business competes with locally owned drugstores, retail drugstore chains, supermarkets, discount retailers, membership clubs, internet companies and other mail-order and long-term care pharmacies

    Our in-house dispensing pharmacy business faces intense competition and extensive state-level regulation of mail-order and controlled substances.

  • Risks Relating to Our Business

    Changes in the prescription drug industry pricing benchmarks may adversely affect our financial performance

    Changes in prescription drug pricing benchmarks like AWP and ASP could adversely affect our financial performance.

  • Risks Relating to Our Business

    Our ability to obtain funds from certain of our licensed subsidiaries is restricted by state insurance regulations

    State insurance regulations restrict our licensed subsidiaries from paying dividends or transferring cash to the parent holding company.

All 22 risk factors

Headings as the filing states them, in filing order.

Risks Relating to Our Business

  1. 01on our ability to appropriately manage health care costs through, among other things, the application of medical management programs such as our chronic care management program
  2. 02Failure to adequately price our products or estimate sufficient benefits payable or effectively manage our operating expenses, may result in a material adverse effect on our results of operations, financial position, and cash flows
  3. 03primary care, and home solutions businesses, and the successful implementation of our integrated care delivery model
  4. 04If we fail to properly maintain the integrity of our data, to strategically maintain existing or implement new information systems, or to protect our proprietary rights to our systems, our business may be materially adversely affected
  5. 05We are involved in various legal actions and governmental and internal investigations, any of which, if resolved unfavorably to us, could result in substantial monetary damages or changes in our business practices. Increased litigation and negative publicity could increase our cost of doing business
  6. 06In some cases, substantial non-economic or punitive damages as well as treble damages under the federal False Claims Act, Racketeer Influenced and Corrupt Organizations Act and other statutes may be sought
  7. 07As a government contractor, we are exposed to risks that may materially adversely affect our business or our willingness or ability to participate in government health care programs
  8. 08conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model
  9. 09Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows
  10. 10New Laws or Regulations, or Future Legislative, Judicial or Regulatory Changes
  11. 11Corporate Practice of Medicine and Other Laws
  12. 12Anti-Kickback, Physician Self-Referral, and Other Fraud and Abuse Laws
  13. 13State Regulation of our Products and Services
  14. 14Any failure by us to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on our results of operations, financial position, and cash flows
  15. 15If we fail to develop and maintain satisfactory relationships with the providers of care to our members, our business may be adversely affected
  16. 16other providers. Any of these events may have a material adverse effect on the provision of services to our members and our results of operations, financial position, and cash flows
  17. 17We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success, and our failure to do so could adversely affect our businesses, operating results and/or future performance
  18. 18Our in-house dispensing pharmacy business competes with locally owned drugstores, retail drugstore chains, supermarkets, discount retailers, membership clubs, internet companies and other mail-order and long-term care pharmacies
  19. 19Changes in the prescription drug industry pricing benchmarks may adversely affect our financial performance
  20. 20Our ability to obtain funds from certain of our licensed subsidiaries is restricted by state insurance regulations
  21. 21Downgrades in our debt ratings, should they occur, may adversely affect our business, results of operations, and financial condition
  22. 22Volatility or disruption in the securities and credit markets, including changes in interest rates, may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio

Other Humana 10-Ks

  • FY2025 10-K risk factors
    21 risks1 new2 dropped3 reworded

    Government programs remained dominant, representing 93% of premiums and services revenue versus 94% last year.

    Filed Feb 19, 2026

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.